LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Elenco Azioni・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Chiusa

SettoreSettore sanitario

31.31 -4.31

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

29.06

Massimo

32.65

Metriche Chiave
By Trading Economics
Entrata	-28M 22M
Vendite	4.3M 244M
P/E Media del settore	11.723 49.8
Margine di Profitto	9.224
Dipendenti	293
EBITDA	-22M 52M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+30.84% upside

Dividendi
By Dow Jones
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	338M 1.9B
Apertura precedente	35.62
Chiusura precedente	31.31

Notizie sul Sentiment di mercato

By Acuity

58%

42%

293 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

29.8 / N/A Supporto e resistenza

Harmony Biosciences Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 mag 2026, 23:58 UTC

Utili

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mag 2026, 22:57 UTC

Utili

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mag 2026, 23:52 UTC

Utili

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mag 2026, 23:45 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mag 2026, 23:28 UTC

Discorsi di Mercato

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mag 2026, 23:11 UTC

Utili

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mag 2026, 23:06 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mag 2026, 23:05 UTC

Utili

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mag 2026, 23:04 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mag 2026, 23:03 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mag 2026, 23:03 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mag 2026, 23:02 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mag 2026, 23:00 UTC

Discorsi di Mercato

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mag 2026, 22:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 mag 2026, 22:45 UTC

Discorsi di Mercato

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mag 2026, 22:42 UTC

Utili

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mag 2026, 22:33 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mag 2026, 22:32 UTC

Utili

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mag 2026, 22:31 UTC

Utili

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mag 2026, 22:31 UTC

Utili

Macquarie: 68% of FY Income From International >MQG.AU

7 mag 2026, 22:30 UTC

Utili

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mag 2026, 22:30 UTC

Utili

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mag 2026, 22:29 UTC

Utili

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mag 2026, 22:28 UTC

Utili

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mag 2026, 22:28 UTC

Utili

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mag 2026, 22:27 UTC

Utili

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mag 2026, 22:27 UTC

Utili

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mag 2026, 22:26 UTC

Utili

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mag 2026, 22:25 UTC

Utili

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Confronto tra pari

Modifica del prezzo

Harmony Biosciences Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

30.84% in crescita

Previsioni per 12 mesi

Media 42.89 USD 30.84%

Alto 72 USD

Basso 25 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

29.8 / N/ASupporto e resistenza

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

293 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.